A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Inclusion Criteria: * Patients with refractory or recurrent Plantar Warts. * No wart treatment for the last 12 weeks * Healthy male or non-pregnant, non-lactating female aged ≥ 18 years or greater * If female of childbearing potential, use an acceptable form of birth control during the study * Provide written informed consent or (HIPAA consent/authorization, as applicable Exclusion Criteria: * Concurrent medical disorder or disease making implementation or interpretation of the protocol or results difficult or unsafe * Female subjects who are breast-feeding or planning to become pregnant * Patients with a history of allergy to silver or fruits * Subjects with clinically significant unstable medical disorder, life threatening disease, or current malignancies * Subjects with History of Alcohol abuse or other drug abuse within 2 years prior to Randomization * Subjects who have been treated with an investigational drug or investigational device within a period of 30 days prior to study enrollment * Concomitant Medications: any other wart therapy is prohibited during the study.